Metronidazole Noridem (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radicals. These radicals damage DNA and essential proteins, leading to loss of cellular function and death of the pathogen, thereby clearing the infection.

The dosage and duration of Metronidazole Noridem are determined by the prescribing clinician according to the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Safety data for metronidazole in pregnancy are limited, and the product is generally avoided in the first trimester. Use during later pregnancy or while breastfeeding should only occur if the potential benefit outweighs the potential risk, under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering a broad spectrum against these organisms. Alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may be used, but metronidazole often provides a more focused approach with a well‑characterized safety profile.

Store at ambient temperature: keep the vial in its original packaging, protect from light, and avoid exposure to moisture. Do not freeze the product. Follow any additional handling instructions provided by the supplier.

Metronidazole Noridem is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified health professional. The infusion rate and duration are set by the prescriber based on the clinical scenario.

Serious risks include seizures, peripheral neuropathy, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, skin reactions, and signs of hypersensitivity, and therapy should be stopped immediately if these occur.

Metronidazole Noridem should be avoided in patients with known hypersensitivity to metronidazole or other nitroimidazoles, in those with severe hepatic impairment, and in early pregnancy unless the benefits clearly outweigh the risks. Caution is also advised for patients with a history of seizures or central nervous system disorders.